MSC -HF Trial: Auto mesenchymal cell transplantation may improve ventricular function in patients with heart failure of ischemic cause

This study is a phase 2, randomized 2:1, double blind, and placebo-controlled included 59 patients with advanced heart failure of ischemic etiology undergoing autologous mesenchymal cells derived from bone marrow through intra- myocardial injection withNoga– XPsystem. The primary end point was the change in end-systolic volume measured by MRI or CT scan at 6 months.A reduction in end-systolic volume with the injection of mesenchymal cells was observed; this was not observed in the placebo group.  Ejection fraction increased in the mesenchymal cell group with an absolute difference of 6.8 % (p < 0.001) .

Conclusion

Improvement in the end-systolic volume and ejection fraction with transplantation of mesenchymal cells in patients with ischemic heart failure was observed.

Original title: Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Severe Ischemic Heart Failure: The MSC-HF Trial.